{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:15:08Z","timestamp":1790936108832,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.berh.2006.05.010","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T16:09:23Z","timestamp":1158682163000},"page":"915-928","source":"Crossref","is-referenced-by-count":60,"title":["B cell depletion therapy in rheumatic disease"],"prefix":"10.1016","volume":"20","author":[{"given":"J.C.W.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cambridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Leandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"supplement 2","key":"10.1016\/j.berh.2006.05.010_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.berh.2006.05.010_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/37.2.126","article-title":"Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen","volume":"37","author":"Edwards","year":"1998","journal-title":"British Journal of Rheumatology"},{"key":"10.1016\/j.berh.2006.05.010_bib3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2006.05.010_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2006.05.010_bib5","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.berh.2006.05.010_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.berh.2006.05.010_bib7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.berh.2006.05.010_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2006.05.010_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.54.9.696","article-title":"Is rheumatoid arthritis a failure of B cell death in synovium?","volume":"54","author":"Edwards","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2006.05.010_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.iy.13.040195.001015","article-title":"The CD19\/CR2\/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity","volume":"13","author":"Fearon","year":"1995","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.berh.2006.05.010_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","article-title":"Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells","volume":"173","author":"Roosnek","year":"1991","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.berh.2006.05.010_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0307-742X(21)00604-4","article-title":"IgG rheumatoid factors and self-association of these antibodies","volume":"11","author":"Mannik","year":"1985","journal-title":"Clinics in Rheumatic Diseases"},{"key":"10.1016\/j.berh.2006.05.010_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nm0797-797","article-title":"Identification of tissue transglutaminase as the autoantigen of celiac disease","volume":"3","author":"Dieterich","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.berh.2006.05.010_bib14","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4049\/jimmunol.168.5.2530","article-title":"Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus","volume":"168","author":"Kaliyaperumal","year":"2002","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.berh.2006.05.010_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00541598","article-title":"Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells","volume":"3","author":"Nardella","year":"1983","journal-title":"Rheumatology International"},{"issue":"1","key":"10.1016\/j.berh.2006.05.010_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2567.1998.00491.x","article-title":"Differential distribution of Fc\u03b3RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments","volume":"94","author":"Bhatia","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.berh.2006.05.010_bib17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO;2-G","article-title":"Induction of tumour necrosis factor alpha production by human monocytes: a key role for Fc\u03b3RIIIa in rheumatoid arthritis","volume":"43","author":"Abrahams","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1699-0463.1997.tb00567.x","article-title":"TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis","volume":"105","author":"Maini","year":"1997","journal-title":"APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica"},{"key":"10.1016\/j.berh.2006.05.010_bib19","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.4049\/jimmunol.144.12.4613","article-title":"A sudy of in vivo immune complex formation and clearance in man","volume":"144","author":"Davies","year":"1990","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.berh.2006.05.010_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib21","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.berh.2006.05.010_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.berh.2006.05.010_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimaeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.berh.2006.05.010_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2006.05.010_bib25","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1042\/bst0300824","article-title":"B lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders","volume":"30","author":"Edwards","year":"2002","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.berh.2006.05.010_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B Lymphocyte depletion therapy with rituximab in rheumatoid arthritis","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheumatic Diseases Clinics of North America"},{"key":"10.1016\/j.berh.2006.05.010_bib27","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serological changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator (BLyS) in rituximab-treated rheumatoid arthritis patients: relation to B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib30","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib31","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B cell targeted therapy with rituximab in rheumatoid arthritis","volume":"35","author":"Edwards","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2006.05.010_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bmt.1704570","article-title":"A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation","volume":"34","author":"Moore","year":"2004","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.berh.2006.05.010_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/03009740310004379","article-title":"Improvement of refractory rheumatoid arthritis after depletion of B cells","volume":"33","author":"Kneitz","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1016\/j.berh.2006.05.010_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.20135","article-title":"Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)","volume":"77","author":"Swords","year":"2004","journal-title":"American Journal of Hematology"},{"issue":"supplement","key":"10.1016\/j.berh.2006.05.010_bib35","first-page":"S709","article-title":"Rituximab in rheumatoid arthritis: a double blind placebo controlled dose-ranging study","volume":"52","author":"Emery","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib36","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib37","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/03009740410010227","article-title":"Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone","volume":"33","author":"van Vollenhoven","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1016\/j.berh.2006.05.010_bib39","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2006.05.010_bib40","unstructured":"Ng K, Leandro MJ, Edwards JC et\u00a0al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases [in press]."},{"key":"10.1016\/j.berh.2006.05.010_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2006.05.010_bib42","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","article-title":"B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus","volume":"52","author":"Marks","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib43","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimaeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"Journal of Internal Medicine"},{"issue":"7","key":"10.1016\/j.berh.2006.05.010_bib46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","article-title":"Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis","volume":"64","author":"Bhatia","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2006.05.010_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib48","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte","year":"2005","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2006.05.010_bib49","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib50","first-page":"ECR34","article-title":"Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome","volume":"89","author":"Erdozain","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.berh.2006.05.010_bib51","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/38.11.1150","article-title":"Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma","volume":"38","author":"Protheroe","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2006.05.010_bib52","first-page":"186","article-title":"Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma","volume":"205","author":"Singh","year":"2005","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"key":"10.1016\/j.berh.2006.05.010_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/gast.2003.50081","article-title":"Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease","volume":"124","author":"Papadakis","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2006.05.010_bib54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2006.05.010_bib55","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.4049\/jimmunol.162.11.6589","article-title":"Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths","volume":"162","author":"Shan","year":"1999","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.berh.2006.05.010_bib56","first-page":"S447","article-title":"Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody)","volume":"50","author":"Kaufman","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.berh.2006.05.010_bib58","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2006.05.010_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opinion on Investigational Drugs"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694206000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694206000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T22:31:47Z","timestamp":1683585107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694206000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S1521694206000702"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2006.05.010","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}